葛酮通络胶囊联合丁苯酞治疗后循环急性脑梗死的疗效及对血清TGF-β1/Smad3信号通路相关蛋白表达、血小板相关因子的影响

doi:10.3969/j.issn.1671-7171.2024.05.023

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1181 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨葛酮通络胶囊联合丁苯酞治疗后循环急性脑梗死(POCI)的疗效及对血清转化生长因子β1(TGF-β1)/Smad3信号通路相关蛋白表达、血小板相关因子的影响。【方法】回顾性分析2020年1月至2023年1月本院收治的114例POCI患者的临床资料,根据治疗方法的不同将其分为观察组和对照组,每组57例。对照组采用丁苯酞治疗,观察组采用葛酮通络胶囊+丁苯酞治疗。比较两组疗效、神经功能缺损评分(NIHSS)、Barthel指数、血清TGF-β1/Smad3信号通路相关蛋白表达(Smad3、TGF-β1、Smad1)、血小板相关因子[血管内皮细胞生长因子(VEGF)、血小板活化因子(PAF)、血管紧张素Ⅱ(AngⅡ)、基质金属蛋白酶9(MMP-9)]、炎症反应指标[可溶性肿瘤坏死因子相关凋亡诱导配体(sTRAIL)、超敏C反应蛋白(hs-CRP)、单核细胞趋化蛋白-1(MCP-1)]。【结果】观察组有效率为94.74%(54/57),高于对照组的80.70%(46/57),差异有统计学意义(χ²=5.211,P=0.022)。治疗后,两组NIHSS评分低于治疗前,且观察组低于对照组,Barthel指数评分高于治疗前,且观察组高于对照组(P<0.05)。治疗后,两组Smad3、TGF-β1、Smad1低于治疗前,且观察组低于对照组(P<0.05)。治疗后,两组血清VEGF水平高于治疗前,且观察组高于对照组,血清PAF、AngⅡ、MMP-9水平低于治疗前,且观察组低于对照组(P<0.05)。治疗后,两组血清hs-CRP、sTRAIL、MCP-1水平低于治疗前,且观察组低于对照组(P<0.05)。【结论】葛酮通络胶囊联合丁苯酞可抑制TGF-β1/Smad3信号通路相关蛋白表达和血小板活化,减轻炎症反应,改善患者神经功能。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	徐小隔
	李静雪
	魏孟丽

关键词 ：脑梗死, 急性病, 苯丙酮类/治疗应用, 转化生长因子β1/血液, 血小板

Abstract：【Objective】To explore the therapeutic effect of Getong Tongluo capsule combined with butylphthalide in the treatment of in posterior circulation infarction (POCI),and its effects on the serum transforming growth factor-β1 (TGF-β1)/Smad3 signaling pathway and platelet related factors.【Methods】A retrospective analysis was conducted on the clinical data of 114 POCI patients admitted to our hospital from January 2020 to January 2023. According to different treatment methods, they were divided into the observation group and the control group, with 57 cases in each group. The control group was treated with butylphthalide, while the observation group was treated with Getong Tongluo capsules and butylphthalide. Two groups were compared in terms of efficacy, National Institute of Health stroke scale (NIHSS),Barthel index, serum TGF -β1/Smad3 signaling pathway related protein expression (Smad3,TGF-β1, Smad1),platelet related factors [vascular endothelial growth factor (VEGF), platelet activating factor (PAF), angiotensin Ⅱ(Ang Ⅱ), matrix metalloproteinase-9 (MMP-9)], inflammatory response indicators [soluble tumor necrosis factor related apoptosis inducing ligand (sTRAIL), hypersensitive C-reactive protein (hs-CRP), monocyte chemotactic protein-1 (MCP-1)].【Results】The effective rate of the observation group was 94.74%(54/57), which was higher than the control group's 80.70%(46/57), and the difference was statistically significant (χ²=5.211, P=0.022). After treatment, the NIHSS scores in both groups were lower than before treatment, and the observation group was lower than the control group. The Barthel index score was higher than that before treatment, and the observation group was higher than the control group (P<0.05). After treatment, Smad3,TGF-β1 and Smad1 of the two groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05). After treatment, the serum VEGF levels in both groups were higher than those before treatment, and the observation group was higher than the control group. The level of the serum PAF,Ang Ⅱ and MMP-9 was lower than those before treatment, and the observation group was lower than the control group (P<0.05). After treatment, the levels of serum hs-CRP, sTRAIL and MCP-1 of the two groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05).【Conclusion】The combination of Getong Tongluo capsules and butylphthalide can inhibit the expression of TGF-β1/Smad3 signaling pathway related proteins, inhibit platelet activation, alleviate inflammatory response, and improve patient neurological function.

Key words： Brain Infarction Acute Disease Propiophenones/TU Transforming Growth Factor beta1/BL Blood Platelets

收稿日期: 2023-08-11

中图分类号:

R743.33

引用本文:

徐小隔, 李静雪, 魏孟丽. 葛酮通络胶囊联合丁苯酞治疗后循环急性脑梗死的疗效及对血清TGF-β1/Smad3信号通路相关蛋白表达、血小板相关因子的影响[J]. 医学临床研究, 2024, 41(5): 725-728.
XU Xiaoge, LI Jingxue, WEI Mengli. The Therapeutic Effect of Getong Tongluo Capsule Combined with Butylphthalide in the Treatment of Acute Posterior Circulation Infarction and its Effect on Serum TGF-β1/Smad3 Signaling Pathway and Platelet Related Factors. JOURNAL OF CLINICAL RESEARCH, 2024, 41(5): 725-728.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.05.023 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I5/725

[1] 陈玉萍,陶晓勇,许胜杰,等.阿加曲班抗凝治疗后循环穿支动脉急性脑梗死疗效及安全性评价[J].中华老年心脑血管病杂志,2022,24(6):611-613.
[2] 石小晶,李秀敏,杨文军,等.丁苯酞注射液联合银杏二萜内酯注射液对急性脑梗死患者的疗效及侧支循环的改善作用[J].河北医药,2021,43(19):2965-2968.
[3] 赵倩煜,刘运海,张金涛,等.葛酮通络胶囊对缺血性脑卒中恢复期病人中医证候改善的多中心随机对照临床研究[J].中西医结合心脑血管病杂志,2021,19(23):4039-4043.
[4] 闫娜,杨妮,董晗,等.芍药苷通过抑制TGF-β1/Smad3通路对急性心肌梗死后心室重塑的作用研究[J].现代中西医结合杂志,2022,31(5):624-629.
[5] 中国中西医结合学会神经科专业委员会.中国脑梗死中西医结合诊治指南(2017)[J].中国中西医结合杂志,2018,38(2):136-144.
[6] 杨秀,欧洲,薛刘军,等.不同年龄后循环急性脑梗死患者阿替普酶静脉溶栓疗效及安全性分析[J].中国医药,2021,16(1):67-70.
[7] 柳美菱子,崔国利,杨慧,等.丁苯酞对急性脑梗死病人血清尾加压素Ⅱ、载脂蛋白A1及神经功能的影响[J].中西医结合心脑血管病杂志,2021,19(21):3772-3774.
[8] 陈明惠,严苗艺,陈颖,等.葛根异黄酮抗缺血性脑卒中作用机制的研究[J].中国临床药理学杂志,2022,38(21):2591-2595.
[9] 田华,郭连军,刘富,等.葛根素下调Atg5、LC3Ⅰ/Ⅱ蛋白对缺血再灌注脑损伤小鼠的神经保护作用[J].中国临床药理学杂志,2023,39(4):508-512.
[10] 高永俊,畅雪丽,杜文贤,等.葛酮通络胶囊联合丁苯酞治疗大动脉粥样硬化型急性脑梗死的疗效及对H-FABP的影响[J].中华中医药学刊,2023,41(2):124-127.
[11] 王礼,段春梅.基于TGF-β1/Smad3信号通路探讨参附注射液对缺血性脑卒中大鼠的神经保护作用[J].中西医结合心脑血管病杂志,2022,20(24):4488-4495.
[12] 黄丽,王磊,吴亚琴,等.血小板活化因子和ABCD3-Ⅰ评分预测老年短暂性脑缺血发作后进展为脑梗死的价值[J].中华老年心脑血管病杂志,2023,25(4):399-403.
[13] 张俊湖,卓军,巩利,等.血清炎性因子和神经细胞因子水平与老年后循环脑梗死患者椎动脉斑块形成及斑块稳定性的关系[J].临床和实验医学杂志,2021,20(10):1066-1069.
[14] 蒋峰,陈正涛,周旭,等.葛根姜黄散治疗脑梗塞的靶点预测及作用机制探究[J].中药新药与临床药理,2022,33(5):633.
[15] 郑国斌,马传瑞,樊官伟.葛根芩连汤治疗动脉粥样硬化的药理学基础研究进展[J].天津中医药大学学报,2022,41(5):668.